Table 3 Clinical benefit rate of ASI with diffident type of vaccines in advanced CRC, post hoc explorative analysis
vaccine | clinical benefit rate |
|---|---|
autologous tumor cell | 20/70(28.6%) |
Peptide vaccine | 45/142(31.7%) |
Viral vector vaccine | 46/163(28.2%) |
DC vaccine | 30/134(22.4%) |